Treatment of myelodysplastic syndrome with agents interfering with inhibitory cytokines.
Where this comes from
- Record sourced from PubMed, PMID 11890651.
- Also identified by PMC identifier 1766670.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Results of these trials provide evidence for biological activity and some clinical efficacy of agents potentially blocking inhibitory cytokines in patients with MDS. However, given the limited responses, it appears that factors additional to TNFalpha inhibitory activity contribute to the development of cytopenias in these patients. Further studies are warranted using anti-TNFalpha/anti-inhibitory cytokine approaches, either alone or in combination with other agents, capable of abrogating the effects of additional inhibitory mechanisms in MDS.
Medical subject headings
- Immunoglobulin G
- Myelodysplastic Syndromes
- Receptors, Tumor Necrosis Factor
- Tumor Necrosis Factor-alpha